These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
395 related articles for article (PubMed ID: 8069001)
1. Interferon beta for multiple sclerosis. Connelly JF Ann Pharmacother; 1994 May; 28(5):610-6. PubMed ID: 8069001 [TBL] [Abstract][Full Text] [Related]
2. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type. Nikfar S; Rahimi R; Abdollahi M Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482 [TBL] [Abstract][Full Text] [Related]
3. Interferon-β-1b: a review of its use in multiple sclerosis. Plosker GL CNS Drugs; 2011 Jan; 25(1):67-88. PubMed ID: 21128695 [TBL] [Abstract][Full Text] [Related]
4. Time-course analysis of CD25 and HLA-DR expression on lymphocytes in interferon-beta 1b-treated multiple sclerosis patients. Ferrarini AM; Sivieri S; Buttarello M; Facchinetti A; Perini P; Gallo P Mult Scler; 1998 Jun; 4(3):174-7. PubMed ID: 9762669 [TBL] [Abstract][Full Text] [Related]
5. Dose and frequency of interferon treatment matter--INCOMIN and OPTIMS. Durelli L J Neurol; 2003 Dec; 250 Suppl 4():IV9-IV14. PubMed ID: 14712396 [TBL] [Abstract][Full Text] [Related]
6. [Current status of interferon beta-1b in multiple sclerosis therapy]. Hartung HP Med Klin (Munich); 2001 Sep; 96 Suppl 1():11-6. PubMed ID: 11603110 [TBL] [Abstract][Full Text] [Related]
7. Lessons from 10 years of interferon beta-1b (Betaferon/Betaseron) treatment. Bayas A; Gold R J Neurol; 2003 Dec; 250 Suppl 4():IV3-8. PubMed ID: 14712395 [TBL] [Abstract][Full Text] [Related]
8. Interferon-beta1b for the treatment of multiple sclerosis. Lam S; Wang S; Gottesman M Expert Opin Drug Metab Toxicol; 2008 Aug; 4(8):1111-7. PubMed ID: 18680445 [TBL] [Abstract][Full Text] [Related]
9. Interferon beta treatment for multiple sclerosis: persisting questions. Goodkin DE Mult Scler; 1996 Jul; 1(6):321-4. PubMed ID: 9345408 [TBL] [Abstract][Full Text] [Related]
10. A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis. Tolley K; Hutchinson M; You X; Wang P; Sperling B; Taneja A; Siddiqui MK; Kinter E PLoS One; 2015; 10(6):e0127960. PubMed ID: 26039748 [TBL] [Abstract][Full Text] [Related]
11. Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b. Antonelli G; Simeoni E; Bagnato F; Pozzilli C; Turriziani O; Tesoro R; Di Marco P; Gasperini C; Fieschi C; Dianzani F J Neurol Sci; 1999 Oct; 168(2):131-6. PubMed ID: 10526196 [TBL] [Abstract][Full Text] [Related]
12. Natural killer cells in relapsing-remitting MS: effect of treatment with interferon beta-1B. Kastrukoff LF; Morgan NG; Zecchini D; White R; Petkau AJ; Satoh J; Paty DW Neurology; 1999 Jan; 52(2):351-9. PubMed ID: 9932956 [TBL] [Abstract][Full Text] [Related]